Funding Opportunities

submenu

News and notices

NOT-CA-17-018

Notice of Correction to PAR-17-095 "Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30)"
This Notice corrects information provided in PAR-17-095, "Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30)" to provide the list of activity codes that qualify as “peer-reviewed, funded research projects"


Anticipated BCRP Funding Opportunities

Department of Defense - Breast Cancer Research Program
FY17 BCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in March 2017. Pre-application and application deadlines will be available when the Program Announcements are released.
-Breakthrough Award
-Breakthrough Fellowship Award
-Era of Hope Scholar Award
-Innovator Award
-Distinguished Investigator Award


NOT-CA-17-006

Notice Award Administration Information for NCI Outstanding Investigator Award (R35)
This notice provides clarification on future NCI grant support to NCI’s Outstanding Investigator Award (OIA) (R35) recipients.  As indicated in the Funding Opportunity Announcement (FOA), future applications submitted after the OIA is awarded will not be folded into the R35 award; however, the 6 calendar month level of effort on the OIA must be maintained for the entire 7-year project period. This Notice clarifies that NCI will only consider funding two additional research project grants to the Outstanding Investigator while the OIA is active.  This limit includes single PD/PI, multiple PD/PI and multi-project grants. In addition, any grant that was relinquished at the time the OIA was awarded should not be submitted for renewal and will not be considered for funding by NCI.


NOT-OD-17-003

Ruth L. Kirschstein National Research Service Awards (NRSA) Postdoctoral Stipends, Training Related Expenses, Institutional Allowance, and Tuition/Fees Effective for Fiscal Year 2017
All FY 2017 awards previously issued using FY 2016 stipend levels will be revised to adjust stipends to the FY 2017 level. Appointments to institutional training grants that have already been awarded in FY 2017 must be amended to reflect the FY 2017 stipend levels once the training grant award has been adjusted by the NIH. Amended appointments must be submitted through xTrain in the eRA Commons.


NOT-OD-17-023

Revised SF424 (R&R) Application Guides and Supplemental Instructions Available

This Notice informs the biomedical and health services research communities that we have updated our application guide and supplemental instructions.
Based on applicant feedback, we have made minor changes to the layout and style of our instructions, located on the How to Apply – Application Guide webpage. We hope that these changes will make it easier for our applicants to find the information they need. We have also incorporated several clarifications to our current Forms-D instructions.


NOT-OD-17-002

NIH Implementation of Final Research Performance Progress Reports (Final RPPR)

The National Institutes of Health intends to replace the Final Progress Report (FPR) with the Final Research Performance Progress Report (Final RPPR) through a new eRA Commons module effective January 2017.


 

Adjustment to Stipend Levels for Postdoctoral Trainees and Fellows on Ruth L. Kirschstein National Research Service Awards (NRSA)

The purpose of this Notice is to announce the process whereby recipients of Kirschstein-NRSA institutional training grant and individual fellowship awards supporting currently active postdoctoral trainees or fellows with 0, 1, or 2 years of experience as of December 1, 2016, will received increased stipends. The Notice also provides instructions for requesting one-time supplemental funding to cover the stipend increase.


 


 

 

External funding opportunities

PAR-16-176

NCI Clinical and Translational Exploratory/Developmental Studies (R21)

This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials.

Funding:

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Key Dates:

Full application due February 21, 2017


Early Detection Targeted Grant

Pancreatic Cancer Action Network
Supports studies utilizing a cohort of new onset diabetics with high risk of sporadic pancreatic cancer; projects will focus on blood biomarkers or imaging strategies

Funding:

Up to $1,000,000 in milestone-driven units of $250,000, up to four years

Key Dates:

Deadline: February 22, 2017, Noon EST


V Foundation Translational Award

V Foundation for Cancer Research
*Internal review coordination through the Masonic Cancer Center

The V Foundation seeks to support translational research projects within the scope of all types of cancers. Definition of a translational research project: Translational projects should move a novel strategy from the laboratory into a human clinical trial or use specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 3 years. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial.

Funding:

A $600,000 grant awarded in three annual installments of $200,000. Indirect costs up to a maximum of 10% within the total award are permitted.

Key Dates:

*MCC Review: One page description, draft budget and biosketch(s) should be emailed to Elizabeth Fedie by 4pm, February 24th.

Full Application: The selected nominee(s) will be required to submit the fully completed application. This must be submitted to SPA by 9am on Friday, April 28th.


V Foundation Pediatric Scholar and/or Translational Award

V Foundation for Cancer Research
*Internal review coordination through the Masonic Cancer Center

The V Scholar Award supports young tenure-track faculty early in their cancer research career by funding projects that are either laboratory-based fundamental research or translational research.

Funding:

Scholar Award: Total $200,000, in two yearly installments of $100,000 each.

Translational Award: Total $600,000, in three yearly installments of $200,000 each. 10% IDC allowed.

Key Dates:

*MCC Review: One page description, draft budget and biosketch(s) should be emailed to Elizabeth Fedie by 4pm, February 24th.

Full Application: The selected nominee will be required to submit the fully completed application. This must be submitted to SPA by 9am on Friday, April 7th.


RFA-CA-17-010

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.

Funding:

$400,000 Direct Costs over a 3-year period, with no more than $200,000 allowed in any single year.

Key Dates:

Full application due February 28, 2017


RFA-CA-17-011

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)

This FOA solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community.

Funding:

$300,000 Direct Costs per year for a maximum of 3 years.

Key Dates:

Full application due February 28, 2017


RFA-CA-17-012

Innovative Technologies for Cancer-Relevant Biospecimen Science (R21)

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

Funding:

Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.

Key Dates:

Full application due February 28, 2017


RFA-CA-17-013

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

This FOA solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

Funding:

Direct costs are limited to $300,000 per year for a maximum of 3 years.

Key Dates:

Full application due February 28, 2017


When Everyone Survives Foundation's 2017 RFP in Leukemia Research

This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Foundation) to solicit innovative research in leukemia. Grants of $50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia. The WES Foundation is supporting leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of “when everyone survives”.  Renewal of initial research support may be considered for one or more additional years based upon productivity.

Funding:

$50,000 in Total Costs, includes Indirect Costs (not to exceed 35%).

Key Dates:

Hard copy submissions are required, and must be received by March 1, 2017.


RFA-CA-17-004

PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24)
The purpose of this funding opportunity announcement (FOA) is to establish a PDXNet Data Commons and Coordinating Center (PDCCC). PDCCC will interact with and coordinate with the PDX (Patient-Derived Xenograft) Development and Trial Centers Research Network (PDXNet) comprised of four PDX Development and Trial Centers (PDTCs, to be supported by companion FOA, RFA-CA-17-003) in a collaborative network. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine. The goals for PDTCs include: development of new PDX models and methods for preclinical testing of single agents and drug combinations; and using the newly established models as well as other existing well-characterized PDX models for studies of drug responses. The PDCCC will serve as the coordinating and data analysis center of the PDXNet. It is expected that the outcomes of PDXNet research will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCI’s Experimental Therapeutic Clinical Trials Network (ETCTN).

Funding:

Application budgets must reflect the actual needs of the proposed project but must not exceed $650,000 per year in direct costs, for a period of 5 years.

Key Dates:

Full application due March 3, 2017


RFA-CA-17-003

PDX Development and Trial Centers (PDTCs)(U54)
This funding opportunity announcement (FOA) solicits applications for PDX (patient-derived xenografts) Development and Trial Centers (PDTCs) to serve as the laboratory research units of the PDX Development and Trial Centers Research Network (PDXNet). The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine.
The main goals for PDTCs include:
Development of new PDX models and methods for preclinical testing of single agents and drug combinations; and
Conducting studies of response of PDX models to novel therapeutic strategies using the newly established models as well as other existing well-characterized PDX models.
It is expected that the outcomes of PDXNet research will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCI’s Experimental Therapeutic Clinical Trials Network (ETCTN).

Funding:

Application budgets must not exceed $800,000 per year in direct costs for period of 5 years.

Key Dates:

Full application due March 3, 2017


RFA-CA-17-009

Mechanisms of Cancer Drug Resistance and Sensitivity (U54)
The goal of this FOA is to create a network of Drug Resistance and Sensitivity Centers (DRSCs) to develop innovative strategies to study mechanisms of tumor resistance or sensitivity to anticancer therapy.  It is hoped that such studies will permit future efforts to identify and exploit these phenomena in clinical settings. Each funded DRSC will become a member of the Drug Resistance and Sensitivity Network.  Each DRSC may include multiple members and capabilities at the same or different institution that are necessary to fulfill the need for highly specialized multidisciplinary expertise.  There may be multiple linked projects within each DSRC that will be under the overall authority of a Program Director/Principal Investigator (PD/PI).  Applications involving several investigators from single or multiple institutions working together on a promising area of cancer resistance or sensitivity to drug therapy are encouraged. The outputs from the DRSCs are expected to inform the development of novel strategies for precision medicine clinical trials (beyond the scope of this FOA) that can overcome drug resistance and sensitivity to anti-cancer agents.

Funding:

$750,000 per year in direct costs, for a max of 5 years.

Key Dates:

Full application due March 3, 2017


2017 PCF Young Investigators Awards RFA

Prostate Cancer Foundation

Applications are encouraged from early-career basic scientists, medical oncologists, pathologists, urologists, radiologists, radiation oncologists, public health experts, bioinformaticians, bioengineers, or professionals from any other field that could contribute to the end of prostate cancer. Applicants may be working in basic, translational, or clinical research and need not be trained specifically in prostate cancer science. However, successful applicants should be working in a research environment capable of supporting transformational prostate cancer research. Access to and interaction with a clinical environment and translational prostate cancer physician-scientists is highly desired. Research proposals submitted in consideration for this award should, if successful, provide high impact to the field. “Small-step” or incremental proposals are usually non-competitive. Highly innovative basic science programs will be carefully considered, but priority will be given to “bench to bedside” translational research proposals with the potential to deliver near term benefit to patients.

Funding:

Awards will be three (3) years in duration and will provide $75,000 per year. The awardfunds may be used flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science.

Key Dates:

Full Application due March 13, 2017


Damon Runyon-Sohn Pediatric Cancer Fellowship Award

The Damon Runyon Cancer Research Foundation

This award provides funding to basic scientists and clinicians who conduct research with the potential to significantly impact the prevention, diagnosis or treatment of one or more pediatric cancers. Applicants are not required to be pediatricians or members of pediatric departments; however, the proposed research must have direct relevance to one or more pediatric cancers. The goal of this Fellowship Award is to recruit the top young minds to research childhood cancers. It leverages the success of the internationally-renowned Damon Runyon Fellowship Award, which has an unparalleled track record for identifying future breakthrough scientists.

Funding:

This four year award is $52,000, $54,000, $57,000 and $60,000 for years one, two, three, and four, respectively. In addition, an annual $2,000 expense allowance is awarded to the laboratory in which the Fellow is working and can be used by the Fellow for his/her educational and scientific expenses. The Foundation also provides a Dependent Child Allowance of $1,000 per child per year. The award may not be used for institutional overhead or indirect costs.

Key Dates:

Full application due March 15, 2017


Melvin and Bren Simon Cancer Center Collaborative Pilot Funding Opportunity

The Vera Bradley Foundation for Breast Cancer/Indiana University

Applications are invited for a collaborative research award to support investigations using the resources (tissue and annotation) of the Susan G. Komen Tissue Bank a (KTB). Potential applicants are encouraged to visit komentissuebank.iu.edu to learn more about the tissue bank’s samples and ongoing research projects. Partnership with a member(s) of the cancer center's breast cancer program, who will provide substantial intellectual and experimental input, is strongly encouraged but is not strictly required.

Funding:

$100,000 maximum (PI’s salary support and indirect cost are not allowed).

Key Dates:

Full application due March 17, 2017


The VBF for Breast Cancer/IUSCC (KTB) Pilot Funding Opportunity  

With support from the Vera Bradley Foundation for Breast Cancer (VBF), the IU Simon Cancer Center breast cancer program invites applications for a collaborative research award to support investigations using the resources (tissue and annotation) of the Komen Tissue Bank (KTB).

Funding:

$100,000 Direct Costs (PI salary and indirect costs not allowed)

Key Dates:

Full application due March 17, 2017
A complete application in PDF format should be sent to Elizabeth Parsons at eparsons@iupui.edu


VBF for Breast Cancer/IUSCC Collaborative Pilot Funding Opportunity 

Together the VBF and the IUSCC Breast Cancer Program (BCP) invite applications from researchers outside IUSCC to initiate new research partnerships. Applicants may propose a new line of inquiry or may use this award to expand work in an ongoing project. Collaboration with a member(s) of IUSCC BCP who will provide substantial intellectual and experimental input is required.

Key Dates:

Full application due March 17, 2017
A complete application in PDF format should be sent to Elizabeth Parsons at eparsons@iupui.edu


PA-17-138

Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer  (Admin Supp)
This Administrative Supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. Based on the recommendation to intensify research and form highly dynamic and collaborative networks of investigators to advance our understanding of fusion oncoproteins as drivers of childhood cancers, this FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations to perform research within the scientific scope of the parent grant that will lead to better understanding of the mechanisms of action of fusion oncoproteins as drivers of childhood sarcomas, brain cancers, and high risk leukemias.

Funding: 

Application budgets are limited to no more than $135,000 Direct Costs per year, regardless of the number of collaborating units. This is exclusive of consortium costs and must reflect the actual needs of the proposed project. Supplement requests may be for up to 2 years.

Key Dates:

Full application due March 28, 2017


RFA: The Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services

The American Cancer Society

A call for research that evaluates the impact of the many changes now occurring in the healthcare system with a particular focus on cancer prevention, control, and treatment. Efforts focusing on improving access to care may also impact inequities that contribute to health disparities. New health public policy initiatives such as the new federal and state marketplaces that have expanded insurance coverage, as well as Medicaid expansion in some states, create natural experiments ripe for evaluation. Research to be funded by this RFA should focus on the changes in national, state, and/or local policy and the response to these changes by healthcare systems, insurers, payers, communities, practices, and patients.

Funding:

Up to 5 years with a budget of up to $400,000 per year (direct costs), plus 20% indirect costs.

Key Dates:

Full application due April 1, 2017


BD Biosciences Cancer Research Grant

A total of $100,000 worth of research reagents are awarded annually to 10 scientists. Through the grant program, BD Biosciences supports scientists pursuing innovative ideas in cancer research, helping to define the next generation of scientific breakthroughs.

Funding:

$100,000 in research reagents

Key dates:

Full Application due April 1, 2017


2017 ACS Grant Application Deadlines

American Cancer Society

Grant programs fund innovative research conducted by hundreds of scientists and healthcare professionals – primarily early in their careers – at institutions nationwide.

Postdoctoral Fellowships- due April 3, 2017

Research Scholar Grants - due April 3, 2017

Mentored Research Scholar Grants - due April 3, 2017

Physician Training Awards in Cancer Prevention - due April 3, 2017


Tina’s Wish Consortium Grant LOI

Tina Brozman Foundation for Ovarian Cancer Research

Letters of Intent are requested for the Tina’s Wish Consortium grant

Tina’s Wish funds researchers proposing new ideas for the early detection or prevention of ovarian cancer. Tina’s Wish believes firmly in the power of collaboration. We established the Tina Brozman Ovarian Cancer Research Consortium, the Tina’s Wish Consortium, to bring together research institutions to collaborate and work together on the early detection and prevention of this disease. The Tina’s Wish Consortium is launching its second consortium grant to support such efforts.

Funding:

Three-year grant, with annual total costs of $300,000. Indirect costs limited to 10%.

Key Dates:

Letter of Intent due April 3, 2017

Invited Full proposals due July 1, 2017


PAR-16-380

Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.

Funding:

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is 5 years.

Key Dates:

Full application due April 11, 2017


2017 PCF Challenge Awards RFA

Prostate Cancer Foundation
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer.  These awards will be funded depending on the level of innovation in applications received.  High risk, currently unfunded projects are most desired.

Funding: 

These awards provide up to $1 million per team.  Cover only direct research costs and travel to the annual PCF Scientific Retreat

Key Dates:

Full applications due April 24, 2017


Mechanisms of Disparities in Chronic Liver Diseases and Cancer - (R21 & R01)

The purpose of the initiative is to support multidisciplinary innovative exploratory and developmental research to understand the underlying etiologic factors and the mechanisms that result in disparities in chronic liver diseases and cancer in the US.
PAR-17-150 (R21)

Funding:

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 direct costs may be requested in any single year.

Key Dates: 

Full application due May 22, 2017
PAR-17-151 (R01)

Funding: 

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years

Key Dates

Full application due May 22, 2017


PAR-17-167

Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01)

This FOA is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.

Funding:

Application budget should reflect the actual needs of the proposed project and is limited to $500,000 in direct costs for the total project period.  No more than $250,000 in direct costs may be requested in any single year.

Key Dates:

Full application due June 28, 2017


Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)

(NOT-OD-15-044)
(PAR-15-075)
National Cancer Institute

Funding:

Standard R01 limits apply

Application Receipt Date(s):

Standard dates apply, by 5:00 PM local time of applicant organization.


NCI Mentored Research Scientist Development Award to Promote Diversity (K01)

(PAR-15-064)
National Cancer Institute

Funding:

$100,000/yr towards salary; $30,000/yr for other expenses

Application Receipt Date(s):

Multiple dates, see announcement.


NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity (K23)

(PAR-15-062)
National Cancer Institute

Application Receipt Date(s):

Multiple dates, see announcement.

Funding:

$100,000/yr towards salary; $30,000/yr for other expenses


National Cancer Institute Program Project Applications (P01)

(PAR-15-023)
National Cancer Institute

Application Receipt Date(s):

Multiple dates, see announcement

Funding:

Varies


Advancing Interventions to Improve Medication Adherence

PA-14-334 – R01 and PA-14-335 – R21
National Cancer Institute

Application Receipt Date(s):

Multiple dates, see announcement.

Funding:

Standard R01 & R21 limit


Role of the Microflora in the Etiology of Gastro-Intestinal Cancer (R01)

(PAR-14-242)
National Cancer Institute

Application Receipt Date(s):  

See announcement for dates.

Funding:

Standard R01 limits apply 


Interventions for Health Promotion and Disease Prevention in Native American Populations (R01)

(PAR-14-260)
National Cancer Institute

Application Receipt Date(s):

See announcement for dates.

Funding:

Standard R01 limits apply.


Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01)

(PA-14-114)
National Cancer Institute

Funding:

Standard R01 limits apply.

Application Receipt Date(s):

Multiple dates, see announcement


Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)

(PAR-14-013)
National Cancer Institute

Funding:

Standard R21 limits apply

Deadline:

See announcement for dates.


Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01)

(PAR-14-116)
National Cancer Institute

Funding:

$500,000/yr for 5 years

Application Receipt Date(s):

Multiple dates, see announcement 


Modeling Social Behavior (R01)

(PAR-13-374)
National Cancer Institute

Funding:

Standard R01 limits apply

Deadline:

Multiple dates, see announcement


Research to Characterize and Reduce Stigma to Improve Health

R01 (PA-13-248), R03 (PA-13-247) and R21 (PA-13-246)

National Cancer Institute

Funding:

Standard limits apply.

Application Receipt Date(s):

Multiple dates, see announcement.  Standard cycle dates.


Innovative Research Methods: Prevention and Management of Symptoms in Chronic Illness

R01 (PA-13-165), R15 (PA-13-166) and R21 (PA-13-167)

National Cancer Institute

Funding:

Standard limits apply. See announcements for additional information

Application Receipt Date(s):

Multiple dates, see announcement.


Bioengineering Research Grants (BRG) (R01)

(PAR-13-137)
National Cancer Institute

Funding:

Standard R01 limits apply.

Application Deadline: 

Multiple receipt dates, see announcement.


Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01)

(PAR-13-169)
National Cancer Institute

Funding:

Standard R01 limits apply

Application Receipt Date(s):

Multiple dates, see announcement.

 

MCC and UMN funding opportunities

Masonic Cancer Center Internal Funding Opportunities

  • V Foundation Translational Award
    V Foundation for Cancer Research

    *Internal review coordination through the Masonic Cancer Center
    The V Foundation seeks to support translational research projects within the scope of all types of cancers. Definition of a translational research project: Translational projects should move a novel strategy from the laboratory into a human clinical trial or use specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 3 years. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial.

    Funding:
    A $600,000 grant awarded in three annual installments of $200,000. Indirect costs up to a maximum of 10% within the total award are permitted.

    Key Dates:
    *MCC Review: One page description, draft budget and biosketch(s) should be emailed to Elizabeth Fedie by 4pm, February 24.
    Full Application: The selected nominee(s) will be required to submit the fully completed application. This must be submitted to SPA by 9am on Friday, April 28.

  • V Foundation Pediatric Scholar and/or Translational Award
    V Foundation for Cancer Research
    *Internal review coordination through the Masonic Cancer Center
    The V Scholar Award supports young tenure-track faculty early in their cancer research career by funding projects that are either laboratory-based fundamental research or translational research.

    Funding:
    Scholar Award: Total $200,000, in two yearly installments of $100,000 each.
    Translational Award: Total $600,000, in three yearly installments of $200,000 each. 10% IDC allowed.

    Key Dates:
    *MCC Review: One page description, draft budget and biosketch(s) should be emailed to Elizabeth Fedie by 4pm, February 24.
    Full Application: The selected nominee will be required to submit the fully completed application. This must be submitted to SPA by 9am on Friday, April 7.

  • Driven to Discover State Fair Grants: Request for Applications 
    The Masonic Cancer Center (MCC) announces its 2017 Driven to Discover at the Minnesota State Fair Grants Program. These grants are designed to support new research ideas that aim to assess or improve cancer treatment and prevention by utilizing the population attending the Minnesota State Fair. Studies funded through this mechanism must enroll and collect data from subjects at the Driven to Discover Research Facility at the 2017 Minnesota State Fair. We invite University of Minnesota faculty who are MCC members to take advantage of this unique opportunity to quickly and efficiently recruit research participants for on-site human-subjects research at the Minnesota State Fair.

    DEADLINES AT A GLANCE
    Applications close: March 3, 2017, 5:00 p.m.
    Notification of Awards: March 15, 2017
    Minnesota State Fair: August 24 – September 4, 2017
     
    Submission Instructions:
    The online application includes request for basic biographical information, lay abstract/synopsis (2-3 sentences), research plan – specific aims, strategy, milestones (2 page max.), references and budget. You will have the opportunity to save the form and finish at a later date.

    Contact or Help in preparation:
    A complete calendar of events is available at Driven to Discover. For questions, help, guidance or more information, contact us at:
    d2d@umn.edu for RFA questions. mccgrant@umn.edu for online application questions

  • Competition for the 2017-2018 Fesler-Lampert Chair
    CURA- Center for Urban and Regional Affairs
    Applications are invited from faculty across the University of Minnesota.

    The Fesler-Lampert Chair in Urban and Regional Affairs was created in 1999 to recognize faculty members with a distinguished record of research and teaching related to matters of urban and regional significance who propose to use the resources of the Chair to undertake research/scholarly activities that will further this work on behalf of the University.

    Funding:
    Historically, the endowment has generated approximately $40,000 to support, for one year, the research activities of a University of Minnesota faculty member for work on a project related to urban and regional affairs in Minnesota. Funds may be used for release time, research assistance, or other support for the project, and may be used for new projects or projects already under way.

    Key Dates: 
    Application materials must be emailed to cura-fl@umn.edu no later than 4:30 pm, March 10.

  • Norm Wells Memorial Colorectal Cancer Fellowship (2016 grant opportunity closed)

Other University of Minnesota Funding Opportunities

Funding resources

Federal agencies funding cancer-related research

  • Search funding opportunities; sign up to receive the NIH Guide weekly via e-mail.
  • Search for funding sources by keyword; sign up for e-mail notification of funding opportunities. (Note: NIH listings are under DHHS, the Department of Health and Human Services.)

Non-federal agencies funding cancer-related research

Research funding directories

CFDA is a database of all federal programs available to state and local governments; federally recognized Indian tribal governments; territories (and possessions) of the United States; domestic public, quasi-public, and private profit and nonprofit organizations and institutions; specialized groups; and individuals.

This funding opportunity search engine provides the world's most comprehensive funding resource, with more than 24,000 records representing nearly 400,000 opportunities ranging from local non-profit funding to federally funded grants.

This is a sortable database of current funding opportunities pulled from various databases. It boasts a user-friendly interface and a comprehensive listing. While the listing is not as comprehensive as other databases in this list, opportunities may be easier to find in this abbreviated format.

(requires x.500 login)

The premier grantseeking database on the Web, developed by the Foundation Center, a national nonprofit service organization founded over 50 years ago to open up U.S. foundations to public view.

A fee-based service, to which the University of Minnesota is a current subscriber. It currently contains over 9,000 active federal and private funding opportunities in the sciences, social sciences, arts, and humanities. In addition to funding opportunities for faculty, the GrantForward Database also contains fellowships and scholarships for grad students and undergrads. Users can search  by sponsor, deadline date, keyword, and other criteria. Most GrantForward records contain live links to sponsor Web sites, electronic forms, or Electronic Research Administration (eRA) portals. The database is updated daily.

InfoEd's SPIN is the most widely used funding opportunity database in the world. By aggregating sponsor information in one system, SPIN dramatically cuts search times and substantially increases the likelihood of positive results. Program information is presented in a standard format that allows investigators to readily compare opportunities. This search engine is great for post-doctoral associates looking for funding opportunities.